Levels of interleukin-6 in second-trimester amniotic fluid are not predictive of adverse neonatal outcome

D. Hasson, C. Y. Spong, A. Ghidini

Research output: Contribution to journalArticle

Abstract

Objective: Elevation of interleukin (IL)-6 in the amniotic fluid (AF) during the second trimester is associated with increased risk of preterm delivery. AF IL-6 levels of > 2950 pg/ml within 72 h of delivery are predictive of neonatal brain white-matter lesions, such as periventricular leukomalacia (PVL). The objective of this study was to evaluate whether the presence of elevated AF IL-6 during the early second trimester was associated with the occurrence of relevant neonatal morbidity including PVL or perinatal mortality. Methods: We performed a historical cohort study of women who underwent mid-trimester amniocentesis and had known AF IF-6 levels and pregnancy outcome information available. Included were singleton gestations, without fetal structural or chromosomal anomalies. Results: Among the 50 woman-neonate pairs included in the study, six had AF IL-6 levels above 2950 pg/ml. Occurrence of neonatal complications requiring admission to the neonatal intensive care unit (14% vs. 33%, p = 0.1) and perinatal mortality (11% vs. 17%, p = 0.7) were not significantly different between cases with elevated vs. normal AF IL-6 levels, respectively. Only one neonate had evidence of PVL; the mid-trimester AF IL-6 level was 296.9 pg/ml, below the established predictive threshold for PVL. The difference between the rate of PVL observed among cases with elevated AF IL-6 (0/5) and that expected on the basis of the literature (43%) approached statistical significance (p = 0.08). Conclusions: Elevated mid-trimester AF IL-6 levels do not identify fetuses at risk for relevant neonatal morbidity or perinatal mortality. Larger studies are required to establish whether mid-trimester AF IL-6 levels can predict the occurrence of neonatal brain white-matter lesions.

Original languageEnglish (US)
Pages (from-to)35-39
Number of pages5
JournalJournal of Maternal-Fetal Medicine
Volume10
Issue number1
StatePublished - Jun 18 2001
Externally publishedYes

Fingerprint

Second Pregnancy Trimester
Amniotic Fluid
Interleukin-6
Periventricular Leukomalacia
Perinatal Mortality
Newborn Infant
Morbidity
Amniocentesis
Neonatal Intensive Care Units
Brain
Infant Mortality
Pregnancy Outcome
Fetus
Cohort Studies
Pregnancy

Keywords

  • Amniotic fluid
  • Interleukin-6
  • Neonatal complications
  • Periventricular leukomalacia

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Levels of interleukin-6 in second-trimester amniotic fluid are not predictive of adverse neonatal outcome. / Hasson, D.; Spong, C. Y.; Ghidini, A.

In: Journal of Maternal-Fetal Medicine, Vol. 10, No. 1, 18.06.2001, p. 35-39.

Research output: Contribution to journalArticle

@article{1bc6125b58d54a3b890c8f501f02bbaa,
title = "Levels of interleukin-6 in second-trimester amniotic fluid are not predictive of adverse neonatal outcome",
abstract = "Objective: Elevation of interleukin (IL)-6 in the amniotic fluid (AF) during the second trimester is associated with increased risk of preterm delivery. AF IL-6 levels of > 2950 pg/ml within 72 h of delivery are predictive of neonatal brain white-matter lesions, such as periventricular leukomalacia (PVL). The objective of this study was to evaluate whether the presence of elevated AF IL-6 during the early second trimester was associated with the occurrence of relevant neonatal morbidity including PVL or perinatal mortality. Methods: We performed a historical cohort study of women who underwent mid-trimester amniocentesis and had known AF IF-6 levels and pregnancy outcome information available. Included were singleton gestations, without fetal structural or chromosomal anomalies. Results: Among the 50 woman-neonate pairs included in the study, six had AF IL-6 levels above 2950 pg/ml. Occurrence of neonatal complications requiring admission to the neonatal intensive care unit (14{\%} vs. 33{\%}, p = 0.1) and perinatal mortality (11{\%} vs. 17{\%}, p = 0.7) were not significantly different between cases with elevated vs. normal AF IL-6 levels, respectively. Only one neonate had evidence of PVL; the mid-trimester AF IL-6 level was 296.9 pg/ml, below the established predictive threshold for PVL. The difference between the rate of PVL observed among cases with elevated AF IL-6 (0/5) and that expected on the basis of the literature (43{\%}) approached statistical significance (p = 0.08). Conclusions: Elevated mid-trimester AF IL-6 levels do not identify fetuses at risk for relevant neonatal morbidity or perinatal mortality. Larger studies are required to establish whether mid-trimester AF IL-6 levels can predict the occurrence of neonatal brain white-matter lesions.",
keywords = "Amniotic fluid, Interleukin-6, Neonatal complications, Periventricular leukomalacia",
author = "D. Hasson and Spong, {C. Y.} and A. Ghidini",
year = "2001",
month = "6",
day = "18",
language = "English (US)",
volume = "10",
pages = "35--39",
journal = "Journal of Maternal-Fetal Medicine",
issn = "1057-0802",
publisher = "Parthenon Publishing Group",
number = "1",

}

TY - JOUR

T1 - Levels of interleukin-6 in second-trimester amniotic fluid are not predictive of adverse neonatal outcome

AU - Hasson, D.

AU - Spong, C. Y.

AU - Ghidini, A.

PY - 2001/6/18

Y1 - 2001/6/18

N2 - Objective: Elevation of interleukin (IL)-6 in the amniotic fluid (AF) during the second trimester is associated with increased risk of preterm delivery. AF IL-6 levels of > 2950 pg/ml within 72 h of delivery are predictive of neonatal brain white-matter lesions, such as periventricular leukomalacia (PVL). The objective of this study was to evaluate whether the presence of elevated AF IL-6 during the early second trimester was associated with the occurrence of relevant neonatal morbidity including PVL or perinatal mortality. Methods: We performed a historical cohort study of women who underwent mid-trimester amniocentesis and had known AF IF-6 levels and pregnancy outcome information available. Included were singleton gestations, without fetal structural or chromosomal anomalies. Results: Among the 50 woman-neonate pairs included in the study, six had AF IL-6 levels above 2950 pg/ml. Occurrence of neonatal complications requiring admission to the neonatal intensive care unit (14% vs. 33%, p = 0.1) and perinatal mortality (11% vs. 17%, p = 0.7) were not significantly different between cases with elevated vs. normal AF IL-6 levels, respectively. Only one neonate had evidence of PVL; the mid-trimester AF IL-6 level was 296.9 pg/ml, below the established predictive threshold for PVL. The difference between the rate of PVL observed among cases with elevated AF IL-6 (0/5) and that expected on the basis of the literature (43%) approached statistical significance (p = 0.08). Conclusions: Elevated mid-trimester AF IL-6 levels do not identify fetuses at risk for relevant neonatal morbidity or perinatal mortality. Larger studies are required to establish whether mid-trimester AF IL-6 levels can predict the occurrence of neonatal brain white-matter lesions.

AB - Objective: Elevation of interleukin (IL)-6 in the amniotic fluid (AF) during the second trimester is associated with increased risk of preterm delivery. AF IL-6 levels of > 2950 pg/ml within 72 h of delivery are predictive of neonatal brain white-matter lesions, such as periventricular leukomalacia (PVL). The objective of this study was to evaluate whether the presence of elevated AF IL-6 during the early second trimester was associated with the occurrence of relevant neonatal morbidity including PVL or perinatal mortality. Methods: We performed a historical cohort study of women who underwent mid-trimester amniocentesis and had known AF IF-6 levels and pregnancy outcome information available. Included were singleton gestations, without fetal structural or chromosomal anomalies. Results: Among the 50 woman-neonate pairs included in the study, six had AF IL-6 levels above 2950 pg/ml. Occurrence of neonatal complications requiring admission to the neonatal intensive care unit (14% vs. 33%, p = 0.1) and perinatal mortality (11% vs. 17%, p = 0.7) were not significantly different between cases with elevated vs. normal AF IL-6 levels, respectively. Only one neonate had evidence of PVL; the mid-trimester AF IL-6 level was 296.9 pg/ml, below the established predictive threshold for PVL. The difference between the rate of PVL observed among cases with elevated AF IL-6 (0/5) and that expected on the basis of the literature (43%) approached statistical significance (p = 0.08). Conclusions: Elevated mid-trimester AF IL-6 levels do not identify fetuses at risk for relevant neonatal morbidity or perinatal mortality. Larger studies are required to establish whether mid-trimester AF IL-6 levels can predict the occurrence of neonatal brain white-matter lesions.

KW - Amniotic fluid

KW - Interleukin-6

KW - Neonatal complications

KW - Periventricular leukomalacia

UR - http://www.scopus.com/inward/record.url?scp=21544468305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21544468305&partnerID=8YFLogxK

M3 - Article

C2 - 11332417

AN - SCOPUS:21544468305

VL - 10

SP - 35

EP - 39

JO - Journal of Maternal-Fetal Medicine

JF - Journal of Maternal-Fetal Medicine

SN - 1057-0802

IS - 1

ER -